Import Alert Guide
Import Alert 16-131 — China Aquaculture, Drug Residues
A plain-language guide to FDA Import Alert 16-131, the countrywide alert allowing detention without physical examination of certain aquacultured seafood from China and Hong Kong for unapproved animal drug residues. What it covers, the charge, the Green List exemption model, and what testing evidence typically involves.
The Short Version
What Is Import Alert 16-131?
Import Alert 16-131 is a countrywide alert that permits FDA to detain, without physical examination, certain aquacultured seafood from China and Hong Kong due to unapproved animal drug residues. Unlike a firm-specific alert, this one applies by origin: covered products from the region are subject to detention unless the firm is on the alert's Green List. The residues at issue — including nitrofurans, malachite green, gentian violet, fluoroquinolones, and mebendazole — are not permitted at any level, and any confirmed detection adulterates the product.
- Alert Number
- 16-131
- Scope
- Countrywide — certain aquacultured seafood from China & Hong Kong SAR
- Species Historically Cited
- Catfish/basa, shrimp & prawns, dace, eel, and related aquaculture products
- Residues
- Nitrofurans, malachite green, gentian (crystal) violet, fluoroquinolones, mebendazole
- Charge
- Adulteration — unsafe new animal drug and/or unsafe food additive (Section 402(a)(2)(C)(ii) & (i))
- Exemption Model
- Green List — firms may be exempted by demonstrating compliance
Official text: FDA Import Alert 16-131.
The Background
Why This Alert Is Countrywide
FDA issued this alert after monitoring found a recurring pattern of unapproved animal drug residues in aquacultured seafood from China — including catfish, basa, shrimp, dace, and eel. Because the pattern spanned the region's supply rather than a single firm, FDA applied detention countrywide.
That structure is the defining feature of 16-131: covered products from China and Hong Kong are presumed violative on arrival simply by origin, and the burden is on the importer to show a specific shipment complies. A firm demonstrates ongoing compliance by earning a place on the alert's Green List, at which point its covered products are exempted from countrywide detention under this alert.
Where an aquacultured product is sourced outside China or Hong Kong but processed there for U.S. export, FDA may look for evidence that adequate controls for unapproved drugs were in place across the full chain — from aquaculture farming through final finished-product processing.
The Evidence
What Per-Shipment Testing Typically Involves
To secure release of an individual detained shipment, the responsible party generally provides third-party laboratory analysis of a representative sample showing the product does not contain the residues at issue for that species.
-
Species-Specific Residue Panel
The residues screened depend on the species — for example, malachite green and leucomalachite green, nitrofuran metabolites, gentian violet, fluoroquinolones (ciprofloxacin and enrofloxacin as a sum), or mebendazole and its metabolites reported as a total.
-
Accredited, Trace-Level Analysis
Methods must detect residues at FDA's low levels. Where LAAF applies to detained food, a LAAF-accredited laboratory is used; laboratory fit and method scope are confirmed during matching.
-
Your Team Submits
Results and custody records are organized into a case file; you and your authorized parties submit to the FDA compliance office named on the notice. FDA may collect audit samples before deciding, and makes the final admissibility decision.
Match the panel to the species. This alert specifies which residues apply to which species, so testing the correct analytes for your exact product is essential. The charge on your notice and the species drive the panel — confirm both before collection. See our laboratory testing coordination guide.
Be Realistic
Green List & What This Alert Means in Practice
Honest limitations
- Countrywide means origin alone triggers detention. A firm can have a spotless record and still see covered shipments detained until it reaches the Green List — that's the nature of a countrywide alert.
- Zero tolerance. There is no acceptable level for these residues; any confirmed detection fails the shipment. Testing cannot change what is in the product.
- Release is not exemption. Winning release of one shipment does not put a firm on the Green List — future covered shipments are still detained until the exemption is granted.
- Green List is documentation-heavy. Exemption commonly requires a run of consecutive third-party-verified released entries plus documentation, from an appropriate authority, that the processor was inspected and operates under adequate farm-to-finished-product controls.
Related
Related Alerts & Guides
Seafood — Unapproved Drugs
The firm-specific counterpart — same drug-residue concern, applied by firm rather than by country.
Read the guide IA 16-81Seafood — Salmonella
The pathogen-side seafood alert — Salmonella rather than drug residues.
Read the guide IndustrySeafood Detention Testing
Category overview: common seafood detention reasons and the testing they typically require.
View industriesAquaculture Seafood Detained Under 16-131?
Bring Us the Notice — We'll Match the Panel to Your Species
Send your FDA Notice of Action with the charge and species, plus product and lot details. You'll get an honest, case-specific read on which residues to test and what coordination can do — before any commitment.
Urgent detention matters receive priority intake review.
FDA Detention Sampling is an independent private company. We are not affiliated with, endorsed by, or part of the U.S. Food and Drug Administration. This guide is a plain-language summary of Import Alert 16-131; the official alert text published by FDA is authoritative and controls. Sampling, laboratory testing, documentation, and coordination services do not guarantee FDA release, admissibility, acceptance of laboratory results, removal from or exemption under any import alert, or any specific regulatory outcome. FDA makes the final admissibility decision.